Developmental Hep C Drug Shows Antiviral Potency
Share
Follow Us
Hepatitis C Phase 2A Trial Positive Results
SYDNEY, Oct. 10, 2011 /PRNewswire via COMTEX/ — Phase 2a trial validates Biotron’s novel drug
First-in-class new, oral drug
Good results on tolerability and efficacy
Full data to be presented to scientific conference in December
Australian drug development company Biotron Limited (asx:BIT) has released headline results from its landmark Phase 2a trial of its lead drug candidate, BIT225 in Hepatitis C virus (HCV) infected patients.
Preliminary analysis of trial data confirms that BIT225, an orally administered, small molecule drug, has good antiviral activity against HCV. Patients receiving BIT225 in combination with interferon and ribavirin (the current standard of care for treating HCV) had greater reductions in HCV levels than patients receiving standard of care treatment alone.
Continue reading this entire article:
http://www.marketwatch.com/story/hepatitis-c-phase-2a-trial-positive-results-2011-10-10
